EP. 5: Closing Perspectives on Advancing Care in EGFR-Positive NSCLC

Joshua Sabari, MD NYU Langone Health | Danny Nguyen, MD City of Hope | Edgardo Santos Castillero, MD, FACP, FASCO The Oncology Institute of Hope and Innovation | Eric Singhi, MD MD Anderson Cancer Center | Alexander Spira, MD, PhD, FACP, FASCO NEXT Oncology

Concluding the discussion, Joshua Sabari, MD, of NYU Langone Health, and the panel reflected on how MARIPOSA and PALOMA trials inform modern EGFR-positive non–small cell lung cancer (NSCLC) management. They emphasized practical application and long-term patient outcomes.

Optimizing Therapy Delivery

Danny Nguyen, MD, of City of Hope, stressed the importance of addressing patient lifestyle, preferences, and logistical considerations. Shared decision-making ensures that therapy aligns with individual priorities and minimizes treatment burden.

Subcutaneous formulations simplify administration and reduce clinic time, noted Alexander Spira, MD, PhD, FACP, FASCO, of NEXT Oncology. Combining proactive adverse event management and efficient delivery allows patients to remain on therapy longer.

Panelists emphasized that EGFR-positive NSCLC treatment is a marathon, not a sprint. Edgardo Santos, MD, FACP, FASCO, of the Oncology Institute of Hope and Innovation, highlighted that dose interruptions and supportive measures do not compromise efficacy, allowing durable therapy over years.

Ongoing surveillance for central nervous system (CNS) progression, resistance mechanisms, and toxicity ensures timely intervention. Eric Singhi, MD, of The University of Texas MD Anderson Cancer Center, noted that identifying complications early enables clinicians to adjust therapy while maintaining effectiveness.

The Importance of Multidisciplinary Engagement

Multidisciplinary engagement, including nurses and patient educators, is critical. Dr. Sabari emphasized that clear communication and patient support improve adherence, quality of life, and clinical outcomes.

Future Outcomes and Evolving Standards of Care

The panel concluded that advances in combination therapies, CNS management, and subcutaneous delivery are transforming EGFR-positive NSCLC care. By integrating these insights, clinicians can maximize survival, minimize toxicity, and enhance patient-centered care in 2025 and beyond.